➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Mallinckrodt
Express Scripts
Dow
McKinsey

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Atogepant


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Atogepant?

Atogepant is an investigational drug.

There have been 10 clinical trials for Atogepant. The most recent clinical trial was a Phase 3 trial, which was initiated on December 14th 2018.

The most common disease conditions in clinical trials are Migraine Disorders and [disabled in preview]. The leading clinical trial sponsors are Allergan, Peking University Third Hospital, and Allergan Limited 1st Floor Marlow International, The Parkway Marlow, Buckinghamshire SL7 lYL.

There are eleven US patents protecting this investigational drug and one hundred and twenty-four international patents.

Recent Clinical Trials for Atogepant
TitleSponsorPhase
Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic MigraineAllerganPhase 3
Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of MigraineAllerganPhase 1
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.AllerganPhase 3

See all Atogepant clinical trials

Clinical Trial Summary for Atogepant

Top disease conditions for Atogepant
Top clinical trial sponsors for Atogepant

See all Atogepant clinical trials

US Patents for Atogepant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Atogepant ⤷  Try it Free Intermediates for preparing CGRP receptor antagonists Merck Sharp & Dohme Corp. (Rahway, NJ) ⤷  Try it Free
Atogepant ⤷  Try it Free Tablet formulation for CGRP active compounds Merck Sharp & Dohme Corp. (Rahway, NJ) ⤷  Try it Free
Atogepant ⤷  Try it Free Piperidinone carboxamide azaindane CGRP receptor antagonists Merck Sharp & Dohme Corp. (Rahway, NJ) ⤷  Try it Free
Atogepant ⤷  Try it Free Piperidinone carboxamide azaindane CGRP receptor antagonists Merck, Sharp & Dohms, Corp. (Rahway, NJ) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Atogepant

Drugname Country Document Number Estimated Expiration Related US Patent
Atogepant European Patent Office EP2849568 2032-05-09 ⤷  Try it Free
Atogepant European Patent Office EP3430906 2032-05-09 ⤷  Try it Free
Atogepant World Intellectual Property Organization (WIPO) WO2013169348 2032-05-09 ⤷  Try it Free
Atogepant Australia AU2015214502 2034-02-05 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Express Scripts
Dow
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.